Amyris
Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. The last earnings update was 121 days ago. More info.
Add to Portfolio Compare Print
- Amyris has significant price volatility in the past 3 months.
AMRS Share Price and Events
7 Day Returns
1 Year Returns
AMRS Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Amyris (AMRS) | -4.1% | -22.2% | -38.6% | -53.8% | -48% | -94.4% |
| US Chemicals | 1.6% | 0.8% | -4.2% | -10.6% | 16.2% | 7.6% |
| US Market | 1.1% | 4.3% | 2.9% | 4.7% | 37.7% | 43.6% |
1 Year Return vs Industry and Market
- AMRS underperformed the Chemicals industry which returned -10.6% over the past year.
- AMRS underperformed the Market in United States of America which returned 4.7% over the past year.
AMRS Value
Is Amyris undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether Amyris is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Amyris has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for Amyris. This is due to cash flow or dividend data being unavailable. The share price is $3.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Amyris's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Amyris's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-3.52 |
| NasdaqGS:AMRS Share Price ** | NasdaqGS (2019-07-16) in USD | $3.08 |
| United States of America Chemicals Industry PE Ratio | Median Figure of 68 Publicly-Listed Chemicals Companies | 18.63x |
| United States of America Market PE Ratio | Median Figure of 3,084 Publicly-Listed Companies | 17.98x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Amyris.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:AMRS Share Price ÷ EPS (both in USD) = 3.08 ÷ -3.52 |
-0.87x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Amyris is loss making, we can't compare its value to the US Chemicals industry average.
- Amyris is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Amyris's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -0.87x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| United States of America Chemicals Industry PEG Ratio | Median Figure of 49 Publicly-Listed Chemicals Companies | 1.43x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.58x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Amyris, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Amyris's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $-2.43 |
| NasdaqGS:AMRS Share Price * | NasdaqGS (2019-07-16) in USD | $3.08 |
| United States of America Chemicals Industry PB Ratio | Median Figure of 93 Publicly-Listed Chemicals Companies | 2.09x |
| United States of America Market PB Ratio | Median Figure of 5,240 Publicly-Listed Companies | 1.81x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:AMRS Share Price ÷ Book Value per Share (both in USD) = 3.08 ÷ -2.43 |
-1.27x |
* Primary Listing of Amyris.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Amyris has negative assets, we can't compare the value of its assets to the US Chemicals industry average.
Value checks
We assess Amyris's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check) Amyris has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
AMRS Future Performance
How is Amyris expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amyris has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Amyris's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Amyris's earnings growth to the United States of America market average as no estimate data is available.
- Unable to compare Amyris's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| United States of America Chemicals Industry Earnings Growth Rate | Market Cap Weighted Average | 12.6% |
| United States of America Chemicals Industry Revenue Growth Rate | Market Cap Weighted Average | 4.9% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14.1% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.5% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (6 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 80 | -213 | |
| 2018-09-30 | 142 | -86 | -162 |
| 2018-06-30 | 151 | -93 | -136 |
| 2018-03-31 | 153 | -101 | -148 |
| 2017-12-31 | 143 | -101 | -93 |
| 2017-09-30 | 85 | -140 | -139 |
| 2017-06-30 | 87 | -104 | -116 |
| 2017-03-31 | 71 | -84 | -119 |
| 2016-12-31 | 67 | -82 | -97 |
| 2016-09-30 | 55 | -78 | -94 |
| 2016-06-30 | 37 | -91 | -151 |
| 2016-03-31 | 35 | -106 | -185 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (6 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Amyris Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -3.52 |
| 2018-09-30 | -3.03 |
| 2018-06-30 | -2.83 |
| 2018-03-31 | -3.68 |
| 2017-12-31 | -2.89 |
| 2017-09-30 | -5.56 |
| 2017-06-30 | -6.02 |
| 2017-03-31 | -6.91 |
| 2016-12-31 | -6.12 |
| 2016-09-30 | -6.37 |
| 2016-06-30 | -11.62 |
| 2016-03-31 | -17.44 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Amyris's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Amyris has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
AMRS Past Performance
How has Amyris performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Amyris does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Amyris's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Amyris's 1-year growth to the US Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Amyris Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 80.42 | -212.61 | 86.92 | |
| 2018-09-30 | 141.65 | -162.27 | 79.01 | |
| 2018-06-30 | 150.98 | -136.49 | 73.44 | |
| 2018-03-31 | 153.46 | -147.89 | 69.27 | |
| 2017-12-31 | 143.45 | -93.37 | 63.29 | |
| 2017-09-30 | 85.10 | -139.21 | 56.92 | |
| 2017-06-30 | 87.44 | -116.10 | 52.85 | |
| 2017-03-31 | 71.36 | -119.40 | 48.23 | |
| 2016-12-31 | 67.19 | -97.33 | 47.72 | |
| 2016-09-30 | 54.80 | -94.32 | 48.46 | |
| 2016-06-30 | 36.85 | -151.28 | 51.18 | |
| 2016-03-31 | 35.09 | -184.85 | 54.15 | |
| 2015-12-31 | 34.15 | -221.78 | 56.26 | |
| 2015-09-30 | 35.89 | -118.01 | 56.57 | 3.51 |
| 2015-06-30 | 43.64 | -77.99 | 56.82 | 3.51 |
| 2015-03-31 | 45.11 | -66.34 | 56.42 | 3.51 |
| 2014-12-31 | 43.27 | 2.29 | 55.44 | |
| 2014-09-30 | 47.09 | -195.16 | 56.18 | |
| 2014-06-30 | 37.75 | -182.72 | 54.88 | |
| 2014-03-31 | 39.29 | -186.11 | 55.62 | |
| 2013-12-31 | 41.12 | -235.11 | 57.05 | 4.28 |
| 2013-09-30 | 31.58 | -139.18 | 60.02 | |
| 2013-06-30 | 43.68 | -135.28 | 64.32 | |
| 2013-03-31 | 52.09 | -143.21 | 71.83 | -1.51 |
| 2012-12-31 | 73.69 | -205.14 | 78.72 | |
| 2012-09-30 | 109.38 | -221.08 | 85.13 | 6.35 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Amyris has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Amyris has efficiently used its assets last year compared to the US Chemicals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Amyris improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Past performance checks
We assess Amyris's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Amyris has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
AMRS Health
How is Amyris's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Amyris's finances.
The net worth of a company is the difference between its assets and liabilities.
- Amyris's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Amyris's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Amyris has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Amyris Company Filings, last reported 6 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -179.44 | 209.91 | 45.35 |
| 2018-09-30 | -205.59 | 171.12 | 19.05 |
| 2018-06-30 | -253.98 | 171.40 | 14.18 |
| 2018-03-31 | -291.21 | 163.06 | 24.08 |
| 2017-12-31 | -199.71 | 165.38 | 57.06 |
| 2017-09-30 | -195.41 | 164.65 | 17.61 |
| 2017-06-30 | -186.52 | 167.70 | 6.63 |
| 2017-03-31 | -211.25 | 223.92 | 2.49 |
| 2016-12-31 | -183.51 | 229.80 | 28.52 |
| 2016-09-30 | -162.50 | 179.10 | 2.30 |
| 2016-06-30 | -154.18 | 184.88 | 2.51 |
| 2016-03-31 | -156.79 | 174.65 | 9.27 |
| 2015-12-31 | -158.46 | 156.98 | 13.51 |
| 2015-09-30 | -141.47 | 158.76 | 11.90 |
| 2015-06-30 | -227.77 | 288.37 | 12.12 |
| 2015-03-31 | -185.92 | 247.08 | 44.95 |
| 2014-12-31 | -125.06 | 236.17 | 43.42 |
| 2014-09-30 | -180.64 | 233.14 | 68.60 |
| 2014-06-30 | -139.68 | 225.16 | 90.21 |
| 2014-03-31 | -112.49 | 181.99 | 49.11 |
| 2013-12-31 | -135.85 | 155.66 | 8.30 |
| 2013-09-30 | 0.42 | 121.91 | 6.34 |
| 2013-06-30 | 20.28 | 110.12 | 12.92 |
| 2013-03-31 | 58.78 | 108.36 | 24.86 |
| 2012-12-31 | 66.23 | 105.53 | 30.69 |
| 2012-09-30 | 76.66 | 106.54 | 44.43 |
- Amyris has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Amyris's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Amyris has less than a year of cash runway based on current free cash flow.
- Amyris has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.1% each year.
Financial health checks
We assess Amyris's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Amyris has a total score of 0/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
AMRS Dividends
What is Amyris's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Amyris
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Amyris's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Amyris's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| United States of America Chemicals Industry Average Dividend Yield | Market Cap Weighted Average of 56 Stocks | 2.2% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2017 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Amyris has not reported any payouts.
- Unable to verify if Amyris's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Amyris's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Amyris afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Amyris has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
AMRS Management
CEO
| COMPENSATION | $1,993,444 |
| AGE | 53 |
| TENURE AS CEO | 12.5 years |
CEO Bio
Mr. John G. Melo has been the Chief Executive Officer at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior management positions of BP plc (formerly British Petroleum) from 1997 to 2006, mostly as President of U.S. Fuels Operations from 2004 to December 2006 and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP's Chief Executive Officer, from 2000 to 2001 and Director of Global Brand Development from 1999 to 2000. In this last role, he helped develop the “Helios” re-branding effort. He successfully led a business transformation and significantly improved the financial performance at BP. He was with Ernst & Young, from 1996 to 1997 and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company and Alldata Corporation. Mr. Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. Mr. Melo serves on the Board of Directors for U.S. Oil, a $1.6 billion energy company and Cilion. He serves as a Director at BayBio and Venture, Inc and Renmatix, Inc. He has been a Director at Amyris, Inc. since January 2007. He served as a Director of KiOR, Inc from July 2010 to February 8, 2012. He served as a Director with Ernst & Young in San Jose, California Life Sciences Association and Bay Area Bioscience Association. Mr. Melo is a Member of the Economic Club of Chicago, The Chicago Club and The Chicago Council on Global Affairs. He serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.
CEO Compensation
- John's compensation has increased whilst company is loss making.
- Insufficient data for John to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Amyris management team in years:
- The average tenure for the Amyris management team is less than 2 years, this suggests a new team.
Management Team
John Melo
President
$2M
53
12.5 yrs
Eduardo Alvarez
Chief Operating Officer
$799K
55
1.8 yrs
Nicole Kelsey
General Counsel & Secretary
$774K
52
1.9 yrs
Kathy Valiasek
Chief Business Officer
$880K
55
0.1 yrs
Fernando de Castro Reinach
Consultant
$57K
64
1 yrs
Jon Wolter
Interim Chief Financial Officer
69
0.1 yrs
Tony Hughes
Chief Accounting Officer
54
1.1 yrs
Peter DeNardo
Director of Investor Relations & Corporate Communications
Beth Baker Bannerman
Senior Vice President of Corporate Communications & Engagement
Christine Ofori
Chief People Officer
Board of Directors Tenure
Average tenure and age of the Amyris board of directors in years:
- The tenure for the Amyris board of directors is about average.
Board of Directors
John Melo
President
$2M
53
12.5 yrs
John Doerr
Independent Director
$61K
67
13.2 yrs
Carole Piwnica
Independent Director
$64K
61
9.8 yrs
Steve Mills
Independent Director
$2M
63
0.9 yrs
R. Williams
Independent Director
$80K
66
6.2 yrs
Geoffrey Duyk
Independent Director
$24K
60
7.2 yrs
Patrick Pichette
Member of Strategic Advisory Board
$47K
56
6.2 yrs
Patrick Yang
Independent Director
$53K
71
5 yrs
Philip Eykerman
Director
$52K
50
2.2 yrs
Frank F. Kung
Director
$22K
70
1.7 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Amyris individual insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 01. May 19 | Buy | Vivo Capital, LLC | Company | 29. Apr 19 | 29. Apr 19 | 913,529 | $4.76 | $4,348,398 | ||
| 26. Apr 19 | Buy | L. Doerr | Individual | 24. Apr 19 | 24. Apr 19 | 2,832,440 | $5.12 | $14,502,093 | ||
| 18. Apr 19 | Buy | L. Doerr | Individual | 15. Apr 19 | 15. Apr 19 | 6,732,369 | $2.87 | $19,321,899 | ||
| 15. Dec 18 | Buy | Eduardo Alvarez | Individual | 13. Dec 18 | 13. Dec 18 | 11,834 | $4.23 | $50,058 | ||
| 27. Nov 18 | Buy | Kathleen Valiasek | Individual | 27. Nov 18 | 27. Nov 18 | 23,000 | $4.37 | $100,574 | ||
| 07. Sep 18 | Buy | Eduardo Alvarez | Individual | 05. Sep 18 | 05. Sep 18 | 11,877 | $8.45 | $100,326 | ||
| 22. Aug 18 | Buy | Kathleen Valiasek | Individual | 22. Aug 18 | 22. Aug 18 | 14,000 | $7.20 | $100,800 | ||
| 22. Aug 18 | Sell | Vivo Capital, LLC | Company | 17. Aug 18 | 17. Aug 18 | -2,439,848 | $6.22 | $-15,172,927 | ||
| 15. Aug 18 | Buy | Patrick Yang | Individual | 13. Aug 18 | 13. Aug 18 | 15,000 | $7.66 | $114,900 | ||
| 13. Aug 18 | Buy | Patrick Yang | Individual | 09. Aug 18 | 09. Aug 18 | 10,000 | $7.71 | $77,100 | ||
Management checks
We assess Amyris's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Amyris has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
AMRS News
Simply Wall St News
What Kind Of Shareholder Appears On The Amyris, Inc.'s (NASDAQ:AMRS) Shareholder Register?
So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Our analysis of the ownership of the company, below, shows that. … institutions own shares in the company.
Simply Wall St - – Full articleAmyris Inc's (NASDAQ:AMRS) Shift From Loss To Profit
With the latest financial year loss of -US$93m and a trailing-twelve month of -US$136m, the US$454m market-cap amplifies its loss by moving further away from its breakeven target? … The most pressing concern for investors is AMRS’s path to profitability – when will it breakeven. … In this article, I will touch on the expectations for AMRS’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleBreaking Down Amyris Inc's (NASDAQ:AMRS) Ownership Structure
In this article, I'm going to take a look at Amyris Inc’s (NASDAQ:AMRS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Ownership structure of a company has been found to affect share performance over time. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.
Simply Wall St - – Full articleWas Amyris Inc's (NASDAQ:AMRS) Earnings Growth Better Than The Industry's?
After looking at Amyris Inc's (NASDAQ:AMRS) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … Check out our latest analysis for Amyris Commentary On AMRS's Past Performance To account for any quarterly or half-yearly updates, I use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … NasdaqGS:AMRS Income Statement May 14th 18 We can further analyze Amyris's loss by looking at what the industry has been experiencing over the past few years.
Simply Wall St - – Full articleWho Are The Major Shareholders Of Amyris Inc (NASDAQ:AMRS)?
AMRS insiders are also influential stakeholders with 7.14% ownership in the company. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Another group of owners that a potential investor in AMRS should consider are private companies, with a stake of 0.048%.
Simply Wall St - – Full articleAmyris Inc's (NASDAQ:AMRS) Profit Outlook
Many investors are wondering the rate at which AMRS will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for AMRS’s growth and when analysts expect the company to become profitable. … Should the business grow at a slower rate, it will become profitable at a later date than expected. … For a more comprehensive look at AMRS, take a look at AMRS’s company page on Simply Wall St.
Simply Wall St - – Full articleShould You Be Holding Amyris Inc (NASDAQ:AMRS) Right Now?
A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Check out our latest analysis for Amyris An interpretation of AMRS's beta Amyris’s beta of 0.5 indicates that the company is less volatile relative to the diversified market portfolio. … AMRS's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns.
Simply Wall St - – Full articleShould Amyris Inc's (NASDAQ:AMRS) Recent Earnings Decline Worry You?
Examining Amyris Inc's (NASDAQ:AMRS) past track record of performance is a useful exercise for investors. … View our latest analysis for Amyris Did AMRS perform worse than its track record and industry? … Amyris's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.
Simply Wall St - – Full articleIs Amyris Inc's (AMRS) CEO Paid Enough Relative To Peers?
Furthermore, Melo's pay is also made up of non-cash items, which means that fluxes in AMRS's share price can impact the actual level of what the CEO actually receives. … Normally I would look at market cap and earnings as a proxy for performance, however, AMRS's negative earnings reduces the usefulness of my formula. … Regardless of whether Melo's pay is above or below peers, the more important factors to look at is AMRS's track record of performance and future outlook moving forward.
Simply Wall St - – Full articleWho Are Amyris Inc's (AMRS) Major Shareholders?
Check out our latest analysis for Amyris NasdaqGS:AMRS Ownership Summary Nov 9th 17 Institutional Ownership With an institutional ownership of 15.44%, AMRS can face volatile stock price movements if institutions execute block trades on the open market, more so, when there are relatively small amounts of shares available on the market to trade Although AMRS has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. … Private Company Ownership Another important group of owners for potential investors in AMRS are private companies that hold a stake of 0.05% in AMRS. … The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.
Simply Wall St - – Full articleAMRS Company Info
Description
Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Details
| Name: | Amyris, Inc. |
| AMRS | |
| Exchange: | NasdaqGS |
| Founded: | 2003 |
| $311,655,153 | |
| 101,186,738 | |
| Website: | http://www.amyris.com |
| Address: |
Amyris, Inc. 5885 Hollis Street, Suite 100, Emeryville, California, 94608, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | AMRS | Common Stock | Nasdaq Global Select | US | USD | 28. Sep 2010 | |
| DB | 3A01 | Common Stock | Deutsche Boerse AG | DE | EUR | 28. Sep 2010 |
Number of employees
Current staff
Industry
| Specialty Chemicals | |
| Materials |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/17 00:21 |
| End of day share price update: | 2019/07/16 00:00 |
| Last estimates confirmation: | 2019/03/18 |
| Last earnings filing: | 2019/03/18 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
